B-Cell activating factor as a cancer biomarker and its implications in cancer-related cachexia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F15%3A%230000631" target="_blank" >RIV/00209805:_____/15:#0000631 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1155/2015/792187" target="_blank" >http://dx.doi.org/10.1155/2015/792187</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2015/792187" target="_blank" >10.1155/2015/792187</a>

Jazyk výsledku

angličtina

Název v původním jazyce

B-Cell activating factor as a cancer biomarker and its implications in cancer-related cachexia

Popis výsledku v původním jazyce

B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily.The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFFantibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor inB-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF?s proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin

Název v anglickém jazyce

B-Cell activating factor as a cancer biomarker and its implications in cancer-related cachexia

Popis výsledku anglicky

B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily.The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFFantibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor inB-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF?s proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BioMed Research international

ISSN

2314-6141

e-ISSN

—

Svazek periodika

2015

Číslo periodika v rámci svazku

2015

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

"article number 792187"

Kód UT WoS článku

000359550200001

EID výsledku v databázi Scopus

2-s2.0-84939839788